🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementFAERS pharmacovigilance data for semaglutide — signal analysis Page 2

FAERS pharmacovigilance data for semaglutide — signal analysis

PharmacoVig_BOS Wed, Jun 3, 2026 at 12:03 AM 18 replies 510 viewsPage 2 of 4
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
Jun 3, 2026 at 3:18 PM#6

The figures, for anyone assembling their own picture. Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.

Last edited: Jun 3, 2026 at 4:18 PM
9 4SleepFixSam, PurityPaulOR, MaxMetOK and 6 others
Reply Quote Save Share Report
nancy_portland
Member
345
1,567
Aug 2024
Portland, ME
Jun 3, 2026 at 9:21 PM#7

One thing that is still open after pete_nash’s answer:

How much of the between-person variation is pharmacokinetic and how much is just adherence measured badly?

8 3KristenIndy, MarkLI_maint, Dr.PeteFamMed and 5 others
Reply Quote Save Share Report
Dr.DermMIA
Member
456
2,123
May 2024
Miami, FL
Jun 4, 2026 at 3:23 AM#8
raj_cambridge said:
Worth knowing that the injection site changes very little.

There is a second half to this that has not been said yet. The dose-response is real but shallow at the top. Across STEP 1 and STEP 4 the gap between 1.7mg and 2.4mg is a couple of percentage points of body weight on average, and the average is carrying a wide spread — plenty of people at 1.7mg sit above the 2.4mg mean. If a dose is working and tolerable, "working" is the relevant variable, not "maximal".

7 2A1cHero_PHX, Dr.RenalNash, LipidDoc_ATL and 4 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Jun 4, 2026 at 9:24 AM#9

Closing the loop on my own question.

Update since I posted: I held at 1.7mg for a further twelve weeks and lost another 4kg slowly, which settles it for me. I was escalating because the number was available, not because I had stopped responding.

6 1kate.chem, DataDave, Dr.GutHealth and 3 others
Reply Quote Save Share Report
Dr.Martinez
Medical Advisor
3,891
28,456
Nov 2023
Boston, MA
Online
Jun 5, 2026 at 2:21 PM#10
Dr.DermMIA said:
The dose-response is real but shallow at the top.

Agreeing with Dr.DermMIA, and the qualification matters more than the agreement. Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

20 18adam_van, Dr.SurgeonPGH, rachel_ABQ and 17 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register